American Brain Tumor Association Awards 11 Research Grants to Advance Brain Tumor Research

American Brain Tumor Association Awards 11 Research Grants to Advance Brain Tumor Research

PR Newswire

CHICAGO, Oct. 30, 2020

CHICAGO, Oct. 30, 2020 /PRNewswire/ — As the nation’s first nonprofit organization committed to funding brain tumor research and providing education and information across all tumor types, the American Brain Tumor Association (ABTA) persists in its mission, announcing today the investment of $368,000 towards 11 new research grants to foster innovation in diagnosis and treatment of brain tumors in adults and children.

American Brain Tumor Association
American Brain Tumor Association

The ABTA’s grant program plays an integral role in advancing the understanding and treatment of brain tumors. Dedicated to investing in early-stage investigators who have unique perspectives to drive the future of brain tumor science and treatment, the ABTA provides research grants to medical students, post-doctoral fellows, and early-career faculty. This investment is even more critical with the COVID-19 pandemic shifting research priorities and impacting government funding for brain tumor research.

“We are excited to continue our legacy of supporting innovative research and early-career researchers, especially during this challenging time. With almost $33 million invested to date, the ABTA is committed to funding the research that will one day lead to cures,” said Nicole Willmarth, Ph.D., chief mission officer, ABTA.

With the Southeastern Brain Tumor Foundation (SBTF) investing more than $100,000 to support three research projects, the ongoing partnership between the ABTA and SBTF exemplifies the strengths of the ABTA’s rigorous grant selection process and accelerates the research investments of both organizations.

“The vast potential of the new projects we fund and the incredible efforts by the researchers, renews my optimism that better treatments are on the horizon. Our collaborations with organizations, like SBTF, amplify our ability to achieve our common goal of improving outcomes for brain tumor patients,” said Nicole Willmarth.

This year’s slate of research investigates critical areas in neuro-oncology research including experimental therapeutics, the role of the immune system and immunotherapies, as well as factors that modify gene function in brain tumor cells.

The ABTA congratulates the 2020 grant recipients listed below. To learn more about the grant recipients and their research projects, visit https://www.abta.org/research/research-funding-impact/.

Basic Research Fellowships are two-year, $100,000 grants awarded to post-doctoral fellows who are mentored by established and nationally-recognized experts in the neuro-oncology field.

  • Emily Darrow, Ph.D., St. Jude Children’s Research Hospital

  • Tyler Miller, M.D., Ph.D., Massachusetts General Hospital

Discovery Grants are one-year, $50,000 grants supporting cutting-edge, innovative approaches that have the potential to change current diagnostic or treatment standards of care for either adult or pediatric brain tumors.

  • Munjal Acharya, Ph.D., University of California, Irvine

  • Lan Hoang-Minh, Ph.D., University of Florida

  • Gary Kohanbash, Ph.D., Children’s Hospital of Pittsburgh

Medical Student Summer Fellowships are $3,000 grants awarded to medical students to conduct brain tumor research projects under the guidance of neuro-oncology experts. Through these grants, the ABTA seeks to encourage physician-scientists to enter and remain in the brain tumor field.

  • Hasan Alrefai, B.S., University of Alabama at

Read more

Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?

When it comes to winning biotech stocks this year, coronavirus vaccine developers automatically come to many investors’ minds. However, one of the top-performing stocks in the sector is Northwest Biotherapeutics (OTC:NWBO), which focuses on immunotherapies that treat cancer, and has returned a staggering 408% since January.

The main reason why investors are so excited about Northwest Biotherapeutics’ prospects is that the company’s 14-year-long phase 3 clinical trial to evaluate its one and only immunotherapy candidate, DCVax-L, as a treatment for glioblastoma, has concluded. Should you consider buying the stock in anticipation of the data release? Let’s find out together. 

3-D illustration of a dendritic cell.

Image source: Getty Images.

Treatment background

Glioblastoma is a deadly form of brain cancer prevalent in up to 15% of people with brain tumors. Even after patients receive standard of care (SOC) treatments consisting of surgery, chemotherapy, and radiotherapy, their median survival time comes down to just 15.5 months in historical studies. DCVax-L is an experimental immunotherapy that seeks to stimulate patients’ own immune systems to fight cancer growth. 

The potential biologic has been in phase 3 clinical trials since December 2006. In the study, all glioblastoma patients receive SOC treatments, while a random portion also receives DCVax-L via upper arm injections. A key trial endpoint requires at least 233 patient deaths out of a total of 331 participants enrolled to calculate a survival benefit for DCVax-L, if any. The company completed its study on July 24, and the data is currently being reviewed by statisticians. In the meantime, speculations on the results have ranged from wildly enthusiastic to pessimistic from excited investors and short-sellers. 

The bullish case

The bullish case for Northwest Biotherapeutics stock is straightforward: The DCVax-L clinical trial was supposed to wrap up as early as November 2016, but had to keep going because the projected number of deaths had not occurred by then.

Around the time when the trial was enrolling, only 3% of glioblastoma patients who received SOC survived over five years. Due to extremely low survival rates for patients who receive SOC treatments, bullish investors argue that there is no other logical explanation for the clinical study going into overtime than DCVax-L keeping patients alive longer than expected. 

The bearish case

The bearish case is a lot more complicated.

Clinical trials investigating experimental biologics for deadly diseases with a lack of therapeutic options usually have pre-planned interim analyses. DCVax-L’s phase 3 trial had two such analyses built into the study.

The analysis is conducted by an independent data-monitoring committee (DMC) that can recommend that the trial stop early if an experimental therapy demonstrates statistically meaningful efficacy against SOC treatments. This way, the biologic can quickly advance to the approval stage in order to save more lives.

Northwest Biotherapeutics’ DMC carried out two interim analyses on the DCVax-L study in 2017 and 2018 (more on this later). Both times, however, the company published the DMC’s findings as blinded, and the trial continued. Unfortunately, that doesn’t make any sense at all in the context of

Read more

VeChain, Renji Hospital and DNV GL Held Strategic Partnership Signing Ceremony To Launch World’s First Blockchain Intelligent Tumor Treatment Center

SHANGHAI, Oct. 27, 2020 /PRNewswire/ — In partnership with VeChain and DNV GL, Renji Hospital, a top-ranked hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has announced the launch of the world’s first blockchain-enabled Intelligent Tumor Treatment Center on October 20, 2020. The Intelligent Tumor Treatment Center is a transparent, efficient, and traceable medical management solution powered by VeChain ToolChainTM.

Sunny Lu, Co-founder and CEO of VeChain & Jidong Zhang, Vice President of Renji Hospital & George Kang, Senior Vice President of DNV GL Group
Sunny Lu, Co-founder and CEO of VeChain & Jidong Zhang, Vice President of Renji Hospital & George Kang, Senior Vice President of DNV GL Group

As strategic partners of this new initiative, VeChain and DNV GL will jointly support the hospital in the quest to improve global public health through state-of-the-art blockchain technology and professional advisory.

VeChain ToolChainTM Powers The World’s First Intelligent Tumor Treatment Center 

The Intelligent Tumor Treatment Center combines the advantages of VeChain blockchain technology with DNV GL’s professional services. It enables full patient ownership of personal medical records, allowing patients to take control of the authorization and medical records data management. Research institutions inside and outside the hospital can use authorized data to improve the efficiency of clinical research, and regulatory agencies can use authorized data to conduct business compliance checks on medical institutions and establish a credit evaluation system.

Zhang Jidong, Vice President of Renji Hospital, said, “The launch of the Intelligent Tumor Treatment Centre intends to enhance high-quality integrated development of Renji Hospital. Moving forward, Renji intends to boost our healthcare facilities with more blockchain-powered use cases and projects, which will be gradually disclosed together with our partners when the time is right.”

George Kang, Senior Vice President of DNV GL Group, said, “Through independent and objective medical evaluation methods, DNV GL intends to provide more services for Renji Hospital to improve its service quality and medical experience, moving to a new stage of higher standards, higher requirements and higher quality.”

Sunny Lu, co-founder and CEO of VeChain, said, “As digital transformation accelerates in the healthcare sector, VeChain will continue to demonstrate its advantages and flexibility as a superior blockchain platform that is suitable for all types of use cases and industries. We are very proud and excited to be contributing to the public health industry by providing the technology for Renji Hospital’s Intelligent Tumor Treatment Centre.”

VeChain Facilitating Digital Transformation To Improve Public Health

In line with the Chinese Government’s 14th Five-Year (2021-2025) Plan for Economic and Social Development, the National Health Commission formulated an official guideline and re-emphasized blockchain technology as an essential innovation and integration of the medical and health industry. VeChain is committed to solving the pain points of digital medical reform through blockchain technology and balancing personal privacy and public interests.

By using the self-developed one-stop data BaaS platform VeChain ToolChainTM , we have many proven cases in the medical sector, including a blockchain powered Clinical Trial Traceability Platform for Bayer China, and a blockchain-enabled medical data management platform named The E-NewHealthLife

Read more

Global Tumor Infiltrating Lymphocytes TIL Immunotherapy Markers Market Size Research Companies Clinical Trials Outlook Report 2025

Tumor Infiltrating Lymphocytes Therapy To Transform The Global Immunotherapy Market Over next Decade Says Kuick Research

DELHI, India, Oct. 22, 2020 (GLOBE NEWSWIRE) — “Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025” Report Highlights:

  • Tumor Infiltrating Lymphocytes Immunotherapy Pipeline: 3 Therapies

  • Highest Phase of Development for Tumor Infiltrating Lymphocytes Immunotherapy : Phase II Trials

  • USA To Dominate Global Tumor Infiltrating Lymphocytes Immunotherapy Market Landscape

  • Expected Cost For Tumor Infiltrating Lymphocytes Immunotherapy: > US$ 200,000

  • TIL Therapy Can Drive Personalized Cancer Therapy Market

Download Report:

https://www.kuickresearch.com/report-global-tumor-tnfiltrating-lymphocytes-immunotherapy-therapy-til-market-size-sales-clinical-trials-lifileucel-ln144-ln145-tilt123

The tumor-infiltrating lymphocyte therapy market is a potent immunotherapy available for the cancer patients but the survival of the therapy in a market where there are plenty of other immunotherapies was not easy. The therapy in a short period of time has made its way through from all the challenges and led to a stage where the availability of the therapy is highly appreciated and praised. The therapy when compared with the other available therapies such as immune checkpoint therapy and monoclonal antibodies is delivering some of the applications that are not observed for other therapies. An important application or advantage of the therapy over the other therapies is the inclination of the tumor-infiltrating lymphocyte therapy market towards personalized therapy. In today’s generation, arrival of personalized therapy is highly appreciated as it has led to an overall survival rate that is more than ever in the past few decades. Also, the therapy has provided the patients with the treatment that is highly required.

All the recent developments that have been characterized have made the therapy produce durable response against the different types of cancer that are prevalent in the patients. Tumor-infiltrating lymphocyte therapy market, above all the therapies that are available is estimated to produce stronger immune response as the technical approach that is coupled with the therapy at laboratory levels are tremendous and fascinating. Being novel and innovative have also led to the arrival of the therapy as a top and pioneering frontier for the pharmaceutical industry.

In the overall development and expansion of the market at a level that is higher than most of the dominating markets of the world, many major research centers and advanced organizations such as National Institute of Health are demonstrating research activity work that is unmatchable with any other ongoing work for other therapies. The market has also achieved a high status when referred to the number of publications that it has done in the past few years. The number of published papers that carry different applications of the therapy has increased multiple times in the past few years. This however indicates the interest of the researchers and the physicians in making the therapy full time available for the cancer patients.

Research work such as the use of TILs in various different cancer types also demonstrated that the combination of autologous TIL and cyclophosphamide could induce regression of metastases and many others have helped the market to establish a landmark in the

Read more
  • Partner links